Seres Therapeutics Inc (NASDAQ:MCRB) was the target of a large growth in short interest in the month of April. As of April 28th, there was short interest totalling 3,106,958 shares, a growth of 14.2% from the April 13th total of 2,721,263 shares. Based on an average daily trading volume, of 167,842 shares, the days-to-cover ratio is presently 18.5 days.
Several analysts recently commented on MCRB shares. FBR & Co reaffirmed an “outperform” rating and set a $18.00 price objective on shares of Seres Therapeutics in a research note on Monday, March 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Seres Therapeutics in a report on Tuesday, March 21st. Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a report on Friday, May 19th. Finally, Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the company a “buy” rating in a report on Thursday, May 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $23.20.
Shares of Seres Therapeutics (NASDAQ:MCRB) opened at 9.72 on Tuesday. Seres Therapeutics has a 52 week low of $8.05 and a 52 week high of $35.98. The firm’s market capitalization is $392.59 million. The company has a 50-day moving average of $9.78 and a 200 day moving average of $10.09. Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.02. The business had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $3 million. During the same quarter in the previous year, the company posted ($0.50) earnings per share. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. Equities research analysts anticipate that Seres Therapeutics will post ($2.63) earnings per share for the current year.
Receive News & Ratings for Seres Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Seres Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.